ALMB-0168

DRUG2 trials

Sponsors

AlaMab Therapeutics (Shanghai) Inc.

Conditions

Advanced Solid Tumors With Bone Only MetastasisOsteosarcoma

Phase 1

A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

AlaMab Therapeutics (Shanghai) Inc.Osteosarcoma

Start: 2021-05-31End: 2024-05-31Target: 238Updated: 2021-05-14

Phase 2

A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed

Not yet recruitingNCT06416358

AlaMab Therapeutics (Shanghai) Inc.Advanced Solid Tumors With Bone Only Metastasis

Start: 2024-05-31End: 2026-12-31Target: 144Updated: 2024-05-16

Related Papers

Evaluation of the safety and efficacy of ALMB-0168, a novel monoclonal antibody activating Cx43 hemichannel, for osteosarcoma after standard therapy failure: A multicenter, open-label, single agent, phase 1/2 study (ACE study).

Journal of Clinical Oncology2025-05-28

ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study.

Journal of Clinical Oncology2023-06-011 citations